|
- HIV prevention drug lenacapavir approved by FDA as twice-yearly . . .
The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99 9% of participants who received it remained HIV negative
- FDA approves powerful HIV prevention drug: What to know
FDA approves powerful HIV drug that nearly eliminated spread in clinical trials The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to
- FDA approves new twice-yearly HIV shot. What to know
The Food and Drug Administration on Wednesday approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections Gilead did
- Gilead Wins Historic Approval for Twice-Yearly HIV Drug
The FDA approved Gilead’s landmark long-acting HIV treatment lenacapavir Wednesday afternoon The drug will be marketed under the name Yeztugo Lenacapavir had already been approved in 2022 and sold under a different name, Sunlenca That approval only applied to patients with treatment-resistant HIV and had received prior treatment
- FDA approves twice-a-year injection for HIV prevention - CNN
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV Gilead Sciences, maker of the
- Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV . . .
Individuals must be tested for HIV-1 infection prior to initiating Yeztugo, and with each subsequent injection of Yeztugo, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection Drug-resistant HIV-1 variants have been identified with use of Yeztugo by individuals with undiagnosed HIV-1 infection
- FDA approves the world’s only twice-a-year shot to prevent HIV
FDA approves the world’s only twice-a-year shot to prevent HIV A pharmacist holds a vial of lenacapavir, an injectable HIV prevention drug, at the Desmond Tutu Health Foundation’s Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead’s lenacapavir drug trial
- For HIV AIDS, FDA approves next best thing to a vaccine | STAT
HIV protection with just two shots a year: FDA approves Gilead drug Lenacapavir, to be sold as Yeztugo, has potential to bring AIDS pandemic to heel but faces Trump-era obstacles Manage alerts for
|
|
|